Spyre Therapeutics Inc
Follow $SYRE
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $SYRE by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is SYRE moving today?
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
SYRE overview
Related filings and maps
Congress activity in SYRE
No receipt-qualified Congressional disclosure is present for SYRE in the cached public ledger.
SYRE contract awards, year to date.
Public federal awards linked to this ticker.
SYRE lobbying filings, year to date.
Registered lobbying filings matched to Spyre Therapeutics Inc.
ARNOLD & PORTER KAYE SCHOLER LLP
ARNOLD & PORTER KAYE SCHOLER LLP
ARNOLD & PORTER KAYE SCHOLER LLP